ANZCTR search results

The study is evaluating whether a diagnostic technique, known as PET scanning, can provide early assessment of response to chemotherapy/targeted therapy in patients with metastatic breast cancer. Who is it for? You may be eligible to join this study if you are a woman aged above 18 years who has been diagnosed with metastatic breast cancer, for which you plan to undergo palliative chemotherapy or tumour targeted therapy. Trial details All participants in this trial will undergo a positron emission tomography (PET) scan pre and post their first cycle of chemotherapy/targeted therapy. A PET scan involves injection of a small amount of radioactive tracer into the bloodstream followed by scanning of the whole body in a machine that looks similar to a CT scan machine for approximately 30 minutes. In addition, participants will undergo standard care, which involves CT scanning after 3-4 cycles of chemotherapy. This study will help us to determine whether PET scanning can accurately assess early response after 1 cycle of chemotherapy/tumour targeted therapy for advanced breast cancer rather than after 3 or 4 cycles required with conventional CT scanning.

The objective of this pilot, exploratory study is to investigate the effects of 4 weeks supplementation with a multivitamin/mineral preparation on brain activity and nutritional status assessed via established functional imaging techniques and blood biomarkers of health in healthy volunteers. Participants will attend two testing sessions, one baseline and one after 4-weeks supplementation. During testing sessions participants will complete a series of common assessments including nutritional status and mood assessment. They will all undergo SST and a sub sample will go on to complete fMRI. Following baseline participants will be randomly assigned to one of two treatments: 1) Berocca Performance 2)Placebo (matched for appearance, taste and smell) Following 4-week daily supplementation with allocated treatment participants will return for their second testing day.

The efficacy of a smoking cessation intervention initiated during a mental health hospital admission and continued post discharge will be assessed via randomised controlled trial. At 12 months post-test, it is hypothesised that participants receiving the intervention will have a 10% points higher 7-day point prevalence abstinence from smoking (20%) as compared to participants that did not (10%), and a 4% points higher prevalence of prolonged abstinence (5%, as compared to 1%).

This study aims to evaluate two cognitive rehabilitation programs in cancer survivors with perceived cognitive dysfunction after chemotherapy. Who is it for? You may be eligible to join this study if you are aged 18 years or above and have had definitive surgery for invasive early cancer within the last 5 years and were treated with adjuvant chemotherapy. You should have completed at least 3 cycles of chemotherapy and be experiencing cognitive changes. Trial details Participants in this trial will be randomly (by chance) allocated to one of three groups. Participants in one group will undergo a structured neurocognitive learning programme (Attention Process Training [APT]) in small groups across 6 weeks for 2 hours per week. Participants in the second group will undergo a systematic teaching of strategies to compensate for the functional impact of cognitive deficit (Compensatory Strategy Training [CST]). Again, this rehabilitation program will be conducted in small 2 hour group sessions over a 6 week period. Participants in the third group will receive standard treatment. Participants will complete questionnaires and cognitive tests at baseline, 4 weeks, 6 months and 12 months post intervention in order to determine the efficacy of the two different cognitive rehabilitation programs.

The purpose of this study is to determine the optimum administration method of glucagon-like peptide-1 (GLP-1), by evaluating whether pulsatile administration of GLP-1 causes greater insulin secretion and glucose lowering when compared with continuous administration.

We are looking at the effects of exercise compared to no exercise on the cardiovascular function in the peripheral (arm) and cerebral (head) arteries. We expect to see a change in the peripheral and cerebral arteries from exercise.

Labelling of food from fast food restaurants has been suggested as one strategy to reduce energy consumption and contribute to reductions in population obesity prevalence. The aim of this study was to examine the effects of two different types of menu labelling techniques (energy and traffic light labelling) on the intended food purchases of children and adults. We are unaware of any past research that directly compares these menu labelling techniques, so our purpose was to determine whether people ordered foods with less total energy content when given a menu with either energy or traffic light labels.

The study aims to identify whether there is reduction in the effect of GLP-1 on gastric emptying with prolonged infusion of GLP-1. Hypothesis The GLP-1's effect of slowing gastric emptying will be reduced over time.

Through local representative Quintiles, Prolong pharmaceuticals would like to conduct Phase I PK study in normal healthy volunteers for its investigational product - SANGUINATE at Nucleus Network, Alfred Hospital, Melbourne, Australia

This proposal will confirm short term benefits of EEN on mucosal recovery and, on follow up, the favorable impact on clinical course. It will demonstrate utility or otherwise of phenotypic, genetic, biomarkers and faecal calprotectin to predict response. Mucosal and microbiome characteristics of patients with mucosal recovery will be compared with non responders to better understand mechanisms of efficacy of EEN with expectation of better targeted, safer, better tolerated, non-pharmacological therapies to induce mucosal healing and improve outcomes for children with Crohn’s disease.